

=> file medicine

FILE 'DRUGMONOG' ACCESS NOT AUTHORIZED

COST IN U.S. DOLLARS

SINCE FILE

ENTRY

TOTAL

SESSION

FULL ESTIMATED COST

38.80

39.01

FILE 'ADISCTI' ENTERED AT 15:21:54 ON 02 SEP 2003

COPYRIGHT (C) 2003 Adis Data Information BV

FILE 'ADISINSIGHT' ENTERED AT 15:21:54 ON 02 SEP 2003

COPYRIGHT (C) 2003 Adis Data Information BV

FILE 'ADISNEWS' ENTERED AT 15:21:54 ON 02 SEP 2003

COPYRIGHT (C) 2003 Adis Data Information BV

FILE 'BIOSIS' ENTERED AT 15:21:54 ON 02 SEP 2003

COPYRIGHT (C) 2003 BIOLOGICAL ABSTRACTS INC.(R)

FILE 'BIOTECHNO' ENTERED AT 15:21:54 ON 02 SEP 2003

COPYRIGHT (C) 2003 Elsevier Science B.V., Amsterdam. All rights reserved.

FILE 'CANCERLIT' ENTERED AT 15:21:54 ON 02 SEP 2003

FILE 'CAPLUS' ENTERED AT 15:21:54 ON 02 SEP 2003

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2003 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'CEN' ENTERED AT 15:21:54 ON 02 SEP 2003

COPYRIGHT (C) 2003 American Chemical Society (ACS)

FILE 'DDFB' ACCESS NOT AUTHORIZED

FILE 'DDFU' ACCESS NOT AUTHORIZED

FILE 'DGENE' ENTERED AT 15:21:54 ON 02 SEP 2003

COPYRIGHT (C) 2003 THOMSON DERWENT

FILE 'DRUGB' ENTERED AT 15:21:54 ON 02 SEP 2003

COPYRIGHT (C) 2003 THOMSON DERWENT

FILE 'DRUGLAUNCH' ENTERED AT 15:21:54 ON 02 SEP 2003

COPYRIGHT (C) 2003 IMSWORLD Publications Ltd

FILE 'DRUGMONOG2' ENTERED AT 15:21:54 ON 02 SEP 2003

COPYRIGHT (C) 2003 IMSWORLD Publications Ltd

FILE 'DRUGNL' ENTERED AT 15:21:54 ON 02 SEP 2003

COPYRIGHT (C) 2003 IMSWORLD Publications Ltd

FILE 'DRUGU' ENTERED AT 15:21:54 ON 02 SEP 2003

COPYRIGHT (C) 2003 THOMSON DERWENT

FILE 'EMBAL' ENTERED AT 15:21:54 ON 02 SEP 2003

COPYRIGHT (C) 2003 Elsevier Science B.V. All rights reserved.

FILE 'EMBASE' ENTERED AT 15:21:54 ON 02 SEP 2003

COPYRIGHT (C) 2003 Elsevier Science B.V. All rights reserved.

FILE 'ESBIOBASE' ENTERED AT 15:21:54 ON 02 SEP 2003

COPYRIGHT (C) 2003 Elsevier Science B.V., Amsterdam. All rights reserved.

FILE 'IFIPAT' ENTERED AT 15:21:54 ON 02 SEP 2003

COPYRIGHT (C) 2003 IFI CLAIMS(R) Patent Services (IFI)

FILE 'IPA' ENTERED AT 15:21:54 ON 02 SEP 2003

COPYRIGHT (C) 2003 American Society of Hospital Pharmacists (ASHP)

FILE 'JICST-EPLUS' ENTERED AT 15:21:54 ON 02 SEP 2003
COPYRIGHT (C) 2003 Japan Science and Technology Corporation (JST)

FILE 'KOSMET' ENTERED AT 15:21:54 ON 02 SEP 2003
COPYRIGHT (C) 2003 International Federation of the Societies of Cosmetics Chemists

FILE 'LIFESCI' ENTERED AT 15:21:54 ON 02 SEP 2003
COPYRIGHT (C) 2003 Cambridge Scientific Abstracts (CSA)

FILE 'MEDICONF' ENTERED AT 15:21:54 ON 02 SEP 2003
COPYRIGHT (c) 2003 FAIRBASE Datenbank GmbH, Hannover, Germany

FILE 'MEDLINE' ENTERED AT 15:21:54 ON 02 SEP 2003

FILE 'NAPRALERT' ENTERED AT 15:21:54 ON 02 SEP 2003
COPYRIGHT (C) 2003 Board of Trustees of the University of Illinois,
University of Illinois at Chicago.

FILE 'NLDB' ENTERED AT 15:21:54 ON 02 SEP 2003
COPYRIGHT (C) 2003 Gale Group. All rights reserved.

FILE 'NUTRACEUT' ENTERED AT 15:21:54 ON 02 SEP 2003
Copyright 2003 (c) MARKETLETTER Publications Ltd. All rights reserved.

FILE 'PASCAL' ENTERED AT 15:21:54 ON 02 SEP 2003
Any reproduction or dissemination in part or in full,
by means of any process and on any support whatsoever
is prohibited without the prior written agreement of INIST-CNRS.
COPYRIGHT (C) 2003 INIST-CNRS. All rights reserved.

FILE 'PCTGEN' ENTERED AT 15:21:54 ON 02 SEP 2003
COPYRIGHT (C) 2003 WIPO

FILE 'PHARMAML' ENTERED AT 15:21:54 ON 02 SEP 2003
Copyright 2003 (c) MARKETLETTER Publications Ltd. All rights reserved.

FILE 'PHIC' ENTERED AT 15:21:54 ON 02 SEP 2003
COPYRIGHT (C) 2003 PJB Publications Ltd. (PJB)

FILE 'PHIN' ENTERED AT 15:21:54 ON 02 SEP 2003
COPYRIGHT (C) 2003 PJB Publications Ltd. (PJB)

FILE 'SCISEARCH' ENTERED AT 15:21:54 ON 02 SEP 2003
COPYRIGHT 2003 THOMSON ISI

FILE 'TOXCENTER' ENTERED AT 15:21:54 ON 02 SEP 2003
COPYRIGHT (C) 2003 ACS

FILE 'USPATFULL' ENTERED AT 15:21:54 ON 02 SEP 2003
CA INDEXING COPYRIGHT (C) 2003 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'USPAT2' ENTERED AT 15:21:54 ON 02 SEP 2003
CA INDEXING COPYRIGHT (C) 2003 AMERICAN CHEMICAL SOCIETY (ACS)

=> s l1 or l2 or l3 or l4 or l5 or l6 or l7 or l8 or l9 or l10 or l11 or l12 or l13 or l14 or
l15 or l16 or l17 or l18 or l19 or l20 or l21 or l22

5 FILES SEARCHED...

'RN' IS NOT A VALID FIELD CODE
'RN' IS NOT A VALID FIELD CODE
'RN' IS NOT A VALID FIELD CODE
'RN' IS NOT A VALID FIELD CODE

13 FILES SEARCHED...

'RN' IS NOT A VALID FIELD CODE

16 FILES SEARCHED...

'RN' IS NOT A VALID FIELD CODE
'RN' IS NOT A VALID FIELD CODE
'RN' IS NOT A VALID FIELD CODE
'RN' IS NOT A VALID FIELD CODE

. 24 FILES SEARCHED...
'RN' IS NOT A VALID FIELD CODE
'RN' IS NOT A VALID FIELD CODE
'RN' IS NOT A VALID FIELD CODE
'RN' IS NOT A VALID FIELD CODE
'RN' IS NOT A VALID FIELD CODE
'RN' IS NOT A VALID FIELD CODE

Zhao, Twyman, Choi, Yong, Gordon, Robert
Boyu
PD 2/27/01

34 FILES SEARCHED...
L23 24 L1 OR L2 OR L3 OR L4 OR L5 OR L6 OR L7 OR L8 OR L9 OR L10 OR
L11 OR L12 OR L13 OR L14 OR L15 OR L16 OR L17 OR L18 OR L19 OR
L20 OR L21 OR L22

=> dup rem

ENTER L# LIST OR (END):123

DUPLICATE IS NOT AVAILABLE IN 'ADISINSIGHT, ADISNEWS, DGENE, DRUGLAUNCH,
DRUGMONOG2, KOSMET, MEDICONF, NUTRACEUT, PCTGEN, PHARMAML'.

ANSWERS FROM THESE FILES WILL BE CONSIDERED UNIQUE

PROCESSING COMPLETED FOR L23

L24 20 DUP REM L23 (4 DUPLICATES REMOVED)

=> d l24 1-20 ibib, kwic

L24 ANSWER 1 OF 20 CAPLUS COPYRIGHT 2003 ACS on STN

ACCESSION NUMBER: 2003:76598 CAPLUS

DOCUMENT NUMBER: 138:117665

TITLE: Carbamate compounds for use in preventing or treating
neuropathic pain and clusters and migraine
headache-associated pain

INVENTOR(S): Codd, Ellen C.; Plata-Salaman, Carlos R.; Zhao, Boyu

PATENT ASSIGNEE(S): Ortho-McNeil Pharmaceutical, Inc., USA

SOURCE: PCT Int. Appl., 34 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003007934	A1	20030130	WO 2000-US221897	20020711

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,
CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,
GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR,
LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH,
PL, PT, RO

RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG,
CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL,
PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR,
NE, SN, TD, TG

US 2003083372	A1	20030501	US 2002-193600	20020711
---------------	----	----------	----------------	----------

PRIORITY APPLN. INFO.: US 2001-305636P P 20010716

OTHER SOURCE(S): MARPAT 138:117665

REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

IT 194085-57-9 194085-57-9D, racemic mixts. or enantiomers

194085-58-0

RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL
(Biological study); USES (Uses)

(carbamate compds. for use in preventing or treating neuropathic pain
and clusters and migraine headache-assocd. pain)

L24 ANSWER 2 OF 20 USPATFULL on STN

ACCESSION NUMBER: 2003:120888 USPATFULL

TITLE: Carbamate compounds for use in preventing or treating
neuropathic pain and cluster and migraine
headache-associated pain

INVENTOR(S): Codd, Ellen C., Blue Bell, PA, UNITED STATES

Plata-Salaman, Carlos R., Ambler, PA, UNITED STATES

Zhao, Boyu, Lansdale, PA, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003083372	A1	20030501
APPLICATION INFO.:	US 2002-193600	A1	20020711 (10)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2001-305636P	20010716 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	AUDLEY A. CIAMPORCERO JR., JOHNSON & JOHNSON, ONE JOHNSON & JOHNSON PLAZA, NEW BRUNSWICK, NJ, 08933-7003	
NUMBER OF CLAIMS:	40	
EXEMPLARY CLAIM:	1	
LINE COUNT:	757	
CAS INDEXING IS AVAILABLE FOR THIS PATENT.		
IT 194085-57-9 194085-57-9D, racemic mixts. or enantiomers 194085-58-0 (carbamate compds. for use in preventing or treating neuropathic pain and clusters and migraine headache-assocd. pain)		

L24 ANSWER 3 OF 20 USPATFULL on STN DUPLICATE 1

ACCESSION NUMBER: 2002:295223 USPATFULL

TITLE: CARBAMATE COMPOUNDS FOR USE IN PREVENTING OR TREATING
PSYCHOTIC DISORDERS

INVENTOR(S): Plata-Salaman, Carlos R., Ambler, PA, UNITED STATES
Zhao, Boyu, Lansdale, PA, UNITED STATES
Twyman, Roy E., Doylestown, PA, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2002165272	A1	20021107
	US 6541513	B2	20030401
APPLICATION INFO.:	US 2002-81761	A1	20020221 (10)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2001-271889P	20010227 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	AUDLEY A. CIAMPORCERO JR., JOHNSON & JOHNSON, ONE JOHNSON & JOHNSON PLAZA, NEW BRUNSWICK, NJ, 08933-7003	
NUMBER OF CLAIMS:	22	
EXEMPLARY CLAIM:	1	
LINE COUNT:	733	
CAS INDEXING IS AVAILABLE FOR THIS PATENT.		
IT 194085-58-0 194085-75-1 (Ph carbamate compds. for use in preventing or treating psychotic disorders)		

L24 ANSWER 4 OF 20 USPATFULL on STN DUPLICATE 2

ACCESSION NUMBER: 2002:273457 USPATFULL

TITLE: Carbamate compounds for use in preventing or treating
movement disorders

INVENTOR(S): Plata-Salaman, Carlos R., Ambler, PA, UNITED STATES
Zhao, Boyu, Lansdale, PA, UNITED STATES
Twyman, Roy E., Doylestown, PA, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2002151585	A1	20021017
	US 6589985	B2	20030708
APPLICATION INFO.:	US 2002-81501	A1	20020221 (10)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2001-271683P	20010227 (60)
DOCUMENT TYPE:	Utility	

FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: AUDLEY A. CIAMPORCERO JR., JOHNSON & JOHNSON, ONE
JOHNSON & JOHNSON PLAZA, NEW BRUNSWICK, NJ, 08933-7003
NUMBER OF CLAIMS: 23
EXEMPLARY CLAIM: 1
LINE COUNT: 709
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
IT 194085-58-0 194085-75-1
(Ph carbamate compds. for use in preventing or treating movement disorders)

L24 ANSWER 5 OF 20 CAPLUS COPYRIGHT 2003 ACS on STN
ACCESSION NUMBER: 2002:675831 CAPLUS
DOCUMENT NUMBER: 137:179915
TITLE: Phenyl carbamate compounds for use in preventing or treating psychotic disorders
INVENTOR(S): Plata-Salaman, Carlos R.; Zhao, Boyu; Twyman, Roy E.
PATENT ASSIGNEE(S): Ortho-McNeil Pharmaceutical, Inc., USA
SOURCE: PCT Int. Appl., 31 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002067927	A1	20020906	WO 2002-US6119	20020221
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
US 2002165272	A1	20021107	US 2002-81761	20020221
US 6541513	B2	20030401		

PRIORITY APPLN. INFO.: US 2001-271889P P 20010227
US 2002-81761 A 20020221

OTHER SOURCE(S): MARPAT 137:179915
REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

IT 194085-58-0 194085-75-1
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(Ph carbamate compds. for use in preventing or treating psychotic disorders)

L24 ANSWER 6 OF 20 CAPLUS COPYRIGHT 2003 ACS on STN
ACCESSION NUMBER: 2002:675830 CAPLUS
DOCUMENT NUMBER: 137:179914
TITLE: Phenyl carbamate compounds for use in preventing or treating movement disorders
INVENTOR(S): Plata-Salaman, Carlos R.; Zhao, Boyu; Twyman, Roy E.
PATENT ASSIGNEE(S): Ortho-McNeil Pharmaceutical, Inc., USA
SOURCE: PCT Int. Appl., 27 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002067926	A1	20020906	WO 2002-US5542	20020221
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,			

GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR,
LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH,
PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ,
UA, UG, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH,
CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR,
BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

US 2002151585 A1 20021017 US 2002-81501 20020221
US 6589985 B2 20030708

PRIORITY APPLN. INFO.: US 2001-271683P P 20010227
US 2002-81501 A 20020221

OTHER SOURCE(S): MARPAT 137:179914

REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

IT 194085-58-0 194085-75-1

RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL
(Biological study); USES (Uses)

(Ph carbamate compds. for use in preventing or treating movement
disorders)

L24 ANSWER 7 OF 20 CAPLUS COPYRIGHT 2003 ACS on STN

ACCESSION NUMBER: 2002:675829 CAPLUS

DOCUMENT NUMBER: 137:179913

TITLE: Phenyl carbamate compounds for use in preventing or
treating neurodegenerative disorders

INVENTOR(S): Plata-Salaman, Carlos R.; Zhao, Boyu; Twyman, Roy E.

PATENT ASSIGNEE(S): Ortho-McNeil Pharmaceutical, Inc., USA

SOURCE: PCT Int. Appl., 34 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
------------	------	------	-----------------	------

WO 2002067925	A1	20020906	WO 2002-US5541	20020221
---------------	----	----------	----------------	----------

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,
CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,
GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR,
LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH,
PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ,
UA, UG, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH,
CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR,
BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

US 2002165273 A1 20021107 US 2002-81764 20020221

PRIORITY APPLN. INFO.: US 2001-271682P P 20010227
US 2002-81764 A 20020221

OTHER SOURCE(S): MARPAT 137:179913

REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

IT 194085-58-0 194085-75-1

RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL
(Biological study); USES (Uses)

(Ph carbamate compds. for use in preventing or treating
neurodegenerative disorders)

L24 ANSWER 8 OF 20 CAPLUS COPYRIGHT 2003 ACS on STN

ACCESSION NUMBER: 2002:675828 CAPLUS

DOCUMENT NUMBER: 137:179912

TITLE: Phenyl carbamate compounds for use in preventing or
treating bipolar disorder

INVENTOR(S): Plata-Salaman, Carlos R.; Zhao, Boyu; Twyman, Roy E.;
Choi, Yong Moon; Gordon, Robert

PATENT ASSIGNEE(S): Ortho-McNeil Pharmaceutical, Inc., USA

SOURCE: PCT Int. Appl., 24 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002067924	A1	20020906	WO 2002-US5425	20020221
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
US 2002193433	A1	20021219	US 2002-81606	20020221
PRIORITY APPLN. INFO.:			US 2001-271680P	P 20010227
			US 2002-81606	A 20020221

OTHER SOURCE(S): MARPAT 137:179912
REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

IT 194085-58-0
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(Ph carbamate compds. for use in preventing or treating bipolar disorder)

L24 ANSWER 9 OF 20 CAPLUS COPYRIGHT 2003 ACS on STN
ACCESSION NUMBER: 2002:675827 CAPLUS
DOCUMENT NUMBER: 137:179911
TITLE: Phenyl carbamate compounds for use in preventing or treating anxiety disorders
INVENTOR(S): Plata-Salaman, Carlos R.; Zhao, Boyu; Twyman, Roy E.
PATENT ASSIGNEE(S): Ortho-McNeil Pharmaceutical, Inc., USA
SOURCE: PCT Int. Appl., 30 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002067923	A1	20020906	WO 2002-US5423	20020221
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
US 2002143053	A1	20021003	US 2002-81713	20020221
PRIORITY APPLN. INFO.:			US 2001-271689P	P 20010227
OTHER SOURCE(S):	MARPAT 137:179911			
REFERENCE COUNT:	4			THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

IT 194085-58-0 194085-75-1
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(Ph carbamate compds. for use in preventing or treating anxiety disorders)

L24 ANSWER 10 OF 20 CAPLUS COPYRIGHT 2003 ACS on STN
ACCESSION NUMBER: 2002:675826 CAPLUS
DOCUMENT NUMBER: 137:179910
TITLE: Phenyl carbamate compounds for use in the treatment of

INVENTOR(S): acute or chronic pain
Plata-Salaman, Carlos R.; Zhao, Boyu; Twyman, Roy E.
PATENT ASSIGNEE(S): Ortho-McNeil Pharmaceutical, Inc., USA
SOURCE: PCT Int. Appl., 28 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002067922	A1	20020906	WO 2002-US5421	20020221
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
US 2002156127	A1	20021024	US 2002-81943	20020221
PRIORITY APPLN. INFO.:		US 2001-271888P P 20010227		

OTHER SOURCE(S): MARPAT 137:179910
REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

IT 194085-58-0 194085-75-1
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(Ph carbamate compds. for use in the treatment of acute or chronic pain)

L24 ANSWER 11 OF 20 USPATFULL on STN
ACCESSION NUMBER: 2002:338065 USPATFULL
TITLE: Carbamate compounds for use in preventing or treating bipolar disorder
INVENTOR(S): Plata-Salaman, Carlos R., Ambler, PA, UNITED STATES
Zhao, Boyu, Lansdale, PA, UNITED STATES
Twyman, Roy E., Doylestown, PA, UNITED STATES
Choi, Yong Moon, Towaco, NJ, UNITED STATES
Gordon, Robert, Robbinsville, NJ, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2002193433	A1	20021219
APPLICATION INFO.:	US 2002-81606	A1	20020221 (10)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2001-271680P	20010227 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	AUDLEY A. CIAMPORCERO JR., JOHNSON & JOHNSON, ONE JOHNSON & JOHNSON PLAZA, NEW BRUNSWICK, NJ, 08933-7003	
NUMBER OF CLAIMS:	17	
EXEMPLARY CLAIM:	1	
LINE COUNT:	577	
CAS INDEXING IS AVAILABLE FOR THIS PATENT.		
IT 194085-58-0	(Ph carbamate compds. for use in preventing or treating bipolar disorder)	

L24 ANSWER 12 OF 20 USPATFULL on STN
ACCESSION NUMBER: 2002:295224 USPATFULL
TITLE: Carbamate compounds for use in preventing or treating neurodegenerative disorders
INVENTOR(S): Plata-Salaman, Carlos R., Ambler, PA, UNITED STATES
Zhao, Boyu, Lansdale, PA, UNITED STATES

Twyman, Roy E., Doylestown, PA, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2002165273	A1	20021107
APPLICATION INFO.:	US 2002-81764	A1	20020221 (10)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2001-271682P	20010227 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	AUDLEY A. CIAMPORCERO JR., JOHNSON & JOHNSON, ONE JOHNSON & JOHNSON PLAZA, NEW BRUNSWICK, NJ, 08933-7003	
NUMBER OF CLAIMS:	32	
EXEMPLARY CLAIM:	1	
LINE COUNT:	873	
CAS INDEXING IS AVAILABLE FOR THIS PATENT.		
IT 194085-58-0 194085-75-1		
(Ph carbamate compds. for use in preventing or treating neurodegenerative disorders)		

L24 ANSWER 13 OF 20 USPATFULL on STN
ACCESSION NUMBER: 2002:280679 USPATFULL
TITLE: Carbamate compounds for use in the treatment of pain
INVENTOR(S): Plata-Salaman, Carlos R., Ambler, PA, UNITED STATES
Zhao, Boyu, Lansdale, PA, UNITED STATES
Twyman, Roy E., Doylestown, PA, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2002156127	A1	20021024
APPLICATION INFO.:	US 2002-81943	A1	20020221 (10)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2001-271888P	20010227 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	AUDLEY A. CIAMPORCERO JR., JOHNSON & JOHNSON, ONE JOHNSON & JOHNSON PLAZA, NEW BRUNSWICK, NJ, 08933-7003	
NUMBER OF CLAIMS:	27	
EXEMPLARY CLAIM:	1	
LINE COUNT:	656	
CAS INDEXING IS AVAILABLE FOR THIS PATENT.		
IT 194085-58-0 194085-75-1		
(Ph carbamate compds. for use in the treatment of acute or chronic pain)		

L24 ANSWER 14 OF 20 USPATFULL on STN
ACCESSION NUMBER: 2002:259477 USPATFULL
TITLE: Carbamate compounds for use in preventing or treating
anxiety disorders
INVENTOR(S): Plata-Salaman, Carlos R., Ambler, PA, UNITED STATES
Zhao, Boyu, Lansdale, PA, UNITED STATES
Twyman, Roy E., Doylestown, PA, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2002143053	A1	20021003
APPLICATION INFO.:	US 2002-81713	A1	20020221 (10)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2001-271689P	20010227 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	AUDLEY A. CIAMPORCERO JR., JOHNSON & JOHNSON, ONE JOHNSON & JOHNSON PLAZA, NEW BRUNSWICK, NJ, 08933-7003	

NUMBER OF CLAIMS: 25
EXEMPLARY CLAIM: 1
LINE COUNT: 732
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
IT 194085-58-0 194085-75-1
(Ph carbamate compds. for use in preventing or treating anxiety disorders)

L24 ANSWER 15 OF 20 CAPLUS COPYRIGHT 2003 ACS on STN DUPLICATE 3
ACCESSION NUMBER: 2001:781465 CAPLUS
DOCUMENT NUMBER: 135:331265
TITLE: Preparation of anticonvulsant halogen-substituted carbamate compounds from 2-phenyl-1,2-ethanediol
INVENTOR(S): Choi, Yong Moon; Kim, Min Woo; Park, Jeonghan
PATENT ASSIGNEE(S): Choi, Yong, USA
SOURCE: U.S. Pat. Appl. Publ., 8 pp., Cont.-in-part of U.S. Ser. No. 220,494, abandoned.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 3
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2001034365	A1	20011025	US 2001-774736	20010131
US 5698588	A	19971216	US 1996-586497	19960116
US 5854283	A	19981229	US 1997-781101	19970109

PRIORITY APPLN. INFO.:
US 1996-586497 A2 19960116
US 1997-781101 A3 19970109
US 1998-220494 B2 19981223

OTHER SOURCE(S): CASREACT 135:331265; MARPAT 135:331265
IT 194085-58-0P 194085-67-1P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(prepn. of anticonvulsant halogen-substituted carbamate compds. from 2-phenyl-1,2-ethanediol)
IT 194085-57-9P 194085-59-1P 194085-60-4P
194085-61-5P 194085-62-6P 194085-63-7P
194085-64-8P 194085-65-9P 194085-66-0P
194085-68-2P 194085-69-3P 194085-70-6P
194085-71-7P 194085-72-8P 194085-73-9P 194085-74-0P
194085-75-1P 194085-76-2P 194085-77-3P 194085-78-4P 194085-79-5P
194085-80-8P 194085-81-9P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of anticonvulsant halogen-substituted carbamate compds. from 2-phenyl-1,2-ethanediol)

L24 ANSWER 16 OF 20 USPATFULL on STN
ACCESSION NUMBER: 2000:131884 USPATFULL
TITLE: Halogen substituted carbamate compounds from 2-phenyl-1,2-ethanediol
INVENTOR(S): Choi, Yong Moon, Towaco, NJ, United States
Kim, Min Woo, Montvale, NJ, United States
Park, Jeonghan, Flanders, NJ, United States
PATENT ASSIGNEE(S): SK Corporation, Fairfield, NJ, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6127412		20001003
APPLICATION INFO.:	US 1999-349852		19990708 (9)
RELATED APPLN. INFO.:	Continuation of Ser. No. US 1998-220494, filed on 23 Dec 1998 which is a division of Ser. No. US 1997-781101, filed on 9 Jan 1997, now patented, Pat.		

No. US 5854283, issued on 29 Dec 1998 which is a continuation-in-part of Ser. No. US 1996-586497, filed on 16 Jan 1996, now patented, Pat. No. US 5698588, issued on 16 Dec 1997

DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Shippen, Michael L.
LEGAL REPRESENTATIVE: Gibbons, Del Deo, Dolan, Griffinger & Vecchione
NUMBER OF CLAIMS: 17
EXEMPLARY CLAIM: 1
LINE COUNT: 561

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT 194085-57-9P 194085-58-0P 194085-59-1P
194085-60-4P 194085-61-5P 194085-62-6P
194085-63-7P 194085-64-8P 194085-65-9P
194085-66-0P 194085-67-1P 194085-68-2P
194085-69-3P 194085-70-6P 194085-71-7P
194085-72-8P 194085-73-9P 194085-74-0P 194085-75-1P
194085-76-2P 194085-77-3P 194085-78-4P 194085-79-5P 194085-80-8P
194085-81-9P
(prepn. of 2-(halophenyl)-2-hydroxyethyl carbamate and dicarbamate
antiepileptics and anticonvulsants)

L24 ANSWER 17 OF 20 USPATFULL on STN

ACCESSION NUMBER: 2000:105942 USPATFULL
TITLE: Halogen substituted carbamate compounds from
2-phenyl-1, 2-ethanediol
INVENTOR(S): Choi, Yong Moon, Towaco, NJ, United States
Kim, Min Woo, Montvale, NJ, United States
Park, Jeonghan, Flanders, NJ, United States
PATENT ASSIGNEE(S): SK Corporation, Fairfield, NJ, United States (U.S.
corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6103759		20000815
APPLICATION INFO.:	US 1999-349850		19990708 (9)
RELATED APPLN. INFO.:	Continuation of Ser. No. US 1998-220494, filed on 23 Dec 1998 which is a division of Ser. No. US 1997-781101, filed on 9 Jan 1997, now patented, Pat. No. US 5854283, issued on 29 Dec 1998 which is a continuation-in-part of Ser. No. US 1996-586497, filed on 16 Jan 1996, now patented, Pat. No. US 5698588, issued on 16 Dec 1997		

DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Shippen, Michael L.
LEGAL REPRESENTATIVE: Gibbons, Del Deo, Dolan, Griffinger & Vecchione
NUMBER OF CLAIMS: 12
EXEMPLARY CLAIM: 1
LINE COUNT: 545

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT 194085-57-9P 194085-58-0P 194085-59-1P
194085-60-4P 194085-61-5P 194085-62-6P
194085-63-7P 194085-64-8P 194085-65-9P
194085-66-0P 194085-67-1P 194085-68-2P
194085-69-3P 194085-70-6P 194085-71-7P
194085-72-8P 194085-73-9P 194085-74-0P 194085-75-1P
194085-76-2P 194085-77-3P 194085-78-4P 194085-79-5P 194085-80-8P
194085-81-9P
(prepn. of 2-(halophenyl)-2-hydroxyethyl carbamate and dicarbamate
antiepileptics and anticonvulsants)

L24 ANSWER 18 OF 20 CAPLUS COPYRIGHT 2003 ACS on STN DUPLICATE 4

ACCESSION NUMBER: 1999:27674 CAPLUS
DOCUMENT NUMBER: 130:81295
TITLE: Preparation of 1-halophenyl-1,2-ethanediol
(di)carbamates as anticonvulsants
INVENTOR(S): Choi, Yong Moon; Kim, Min Woo; Park, Jeonghan

PATENT ASSIGNEE(S): Yukong Limited, S. Korea
SOURCE: U.S., 8 pp., Cont.-in-part of U.S. 5,698,588.
CODEN: USXXAM
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 3
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 5854283	A	19981229	US 1997-781101	19970109
US 5698588	A	19971216	US 1996-586497	19960116
CA 2242865	AA	19970724	CA 1997-2242865	19970116
CN 1208402	A	19990217	CN 1997-191722	19970116
CN 1077567	B	20020109		
RU 2171800	C2	20010810	RU 1998-115573	19970116
JP 2002515029	T2	20020521	JP 1997-525878	19970116
ES 2184058	T3	20030401	ES 1997-900794	19970116
US 6103759	A	20000815	US 1999-349850	19990708
US 6127412	A	20001003	US 1999-349852	19990708
US 2001034365	A1	20011025	US 2001-774736	20010131

PRIORITY APPLN. INFO.:
US 1996-586497 A2 19960116
US 1997-781101 A 19970109
WO 1997-KR6 W 19970116
US 1998-220494 A1 19981223

OTHER SOURCE(S): MARPAT 130:81295

REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

IT 194085-57-9P 194085-58-0P 194085-59-1P
194085-60-4P 194085-61-5P 194085-62-6P
194085-63-7P 194085-64-8P 194085-65-9P
194085-66-0P 194085-67-1P 194085-68-2P
194085-69-3P 194085-70-6P 194085-71-7P
194085-72-8P 194085-73-9P 194085-75-1P 194085-76-2P
194085-77-3P 194085-78-4P 194085-79-5P 194085-80-8P 194085-81-9P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of 1-halophenyl-1,2-ethanediol (di)carbamates as anticonvulsants)

L24 ANSWER 19 OF 20 CAPLUS COPYRIGHT 2003 ACS on STN

ACCESSION NUMBER: 1997:499169 CAPLUS

DOCUMENT NUMBER: 127:176276

TITLE: Preparation of 2-(halophenyl)-2-hydroxyethyl carbamate and dicarbamate antiepileptics and anticonvulsants

INVENTOR(S): Choi, Yong Moon; Kim, Min Woo; Park, Jeong Han

PATENT ASSIGNEE(S): Yukong Ltd, S. Korea

SOURCE: PCT Int. Appl., 29 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 3

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9726241	A1	19970724	WO 1997-KR6	19970116
W: AU, CA, CN, JP, RU				
RW: AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
US 5698588	A	19971216	US 1996-586497	19960116
AU 9713205	A1	19970811	AU 1997-13205	19970116
AU 724812	B2	20000928		
EP 907635	A1	19990414	EP 1997-900794	19970116
EP 907635	B1	20020925		
R: BE, CH, DE, ES, FR, GB, IT, LI, SE				
RU 2171800	C2	20010810	RU 1998-115573	19970116
JP 2002515029	T2	20020521	JP 1997-525878	19970116

PRIORITY APPLN. INFO.: US 1996-586497 A 19960116

US 1997-781101 A 19970109
WO 1997-KR6 W 19970116

OTHER SOURCE(S): MARPAT 127:176276

IT 194085-57-9P 194085-58-0P 194085-59-1P
194085-60-4P 194085-61-5P 194085-62-6P
194085-63-7P 194085-64-8P 194085-65-9P
194085-66-0P 194085-67-1P 194085-68-2P
194085-69-3P 194085-70-6P 194085-71-7P
194085-72-8P 194085-73-9P 194085-74-0P 194085-75-1P
194085-76-2P 194085-77-3P 194085-78-4P 194085-79-5P 194085-80-8P
194085-81-9P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of 2-(halophenyl)-2-hydroxyethyl carbamate and dicarbamate antiepileptics and anticonvulsants)

L24 ANSWER 20 OF 20 USPATFULL on STN

ACCESSION NUMBER: 97:118078 USPATFULL

TITLE: Halogen substituted carbamate compounds from 2-phenyl-1,2-ethanediol

INVENTOR(S): Choi, Yong Moon, Towaco, NJ, United States
Kim, Min Woo, Montville, NJ, United States

PATENT ASSIGNEE(S): Yukong Limited, Seoul, Korea, Republic of (non-U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5698588		19971216
APPLICATION INFO.:	US 1996-586497		19960116 (8)
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	Granted		
PRIMARY EXAMINER:	Shippen, Michael L.		
LEGAL REPRESENTATIVE:	Abelman, Frayne & Schwab		
NUMBER OF CLAIMS:	7		
EXEMPLARY CLAIM:	1,3		
LINE COUNT:	351		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT 194085-57-9P 194085-58-0P 194085-59-1P
194085-60-4P 194085-61-5P 194085-62-6P
194085-63-7P 194085-64-8P 194085-65-9P
194085-66-0P 194085-67-1P 194085-68-2P
194085-69-3P 194085-70-6P 194085-71-7P
194085-72-8P 194085-73-9P 194085-74-0P 194085-75-1P
194085-76-2P 194085-77-3P 194085-78-4P 194085-79-5P 194085-80-8P
194085-81-9P

(prepn. of 2-(halophenyl)-2-hydroxyethyl carbamate and dicarbamate antiepileptics and anticonvulsants)

=> s manic or bipolar or depressive or manic-depressive or psychotic

35 FILES SEARCHED...

L25 548913 MANIC OR BIPOLAR OR DEPRESSIVE OR MANIC-DEPRESSIVE OR PSYCHOTIC

=> d his

(FILE 'HOME' ENTERED AT 15:13:36 ON 02 SEP 2003)

FILE 'REGISTRY' ENTERED AT 15:14:09 ON 02 SEP 2003

L1 0 S 194085580P/RN
L2 0 S 194085-67-1P/RN
L3 1 S 194085-58-0/RN
L4 1 S 194085-67-1/RN
L5 1 S 194085-57-9/RN
L6 1 S 194085-61-5/RN
L7 1 S 194085-64-8/RN
L8 1 S 194085-68-2/RN
L9 1 S 194085-71-7/RN

L10 1 S 194085-60-4/RN
L11 1 S 194085-60-4/RN
L12 1 S 194085-61-5/RN
L13 1 S 194085-62-6/RN
L14 1 S 194085-63-7/RN
L15 1 S 194085-64-8/RN
L16 1 S 194085-65-9/RN
L17 1 S 194085-66-0/RN
L18 1 S 194085-68-2/RN
L19 1 S 194085-69-3/RN
L20 1 S 194085-70-6/RN
L21 1 S 194085-71-7/RN
L22 1 S 194085-72-8/RN

FILE 'ADISCTI, ADISINSIGHT, ADISNEWS, BIOSIS, BIOTECHNO, CANCERLIT, CAPLUS, CEN, DGENE, DRUGB, DRUGLAUNCH, DRUGMONOG2, DRUGNL, DRUGU, EMBAL, EMBASE, ESBIODBASE, IFIPAT, IPA, JICST-EPLUS, KOSMET, LIFESCI, MEDICONF, MEDLINE, NAPRALERT, NLDB, NUTRACEUT, ...' ENTERED AT 15:21:54 ON 02 SEP 2003

L23 24 S L1 OR L2 OR L3 OR L4 OR L5 OR L6 OR L7 OR L8 OR L9 OR L10 OR
L24 20 DUP REM L23 (4 DUPLICATES REMOVED)
L25 548913 S MANIC OR BIPOLAR OR DEPRESSIVE OR MANIC-DEPRESSIVE OR PSYCHOT

=> s l24 and l25
L26 4 L24 AND L25

=> d l26 ibib, kwic

L26 ANSWER 1 OF 4 CAPLUS COPYRIGHT 2003 ACS on STN

ACCESSION NUMBER: 2002:675831 CAPLUS

DOCUMENT NUMBER: 137:179915

TITLE: Phenyl carbamate compounds for use in preventing or treating **psychotic** disorders

INVENTOR(S): Plata-Salaman, Carlos R.; Zhao, Boyu; Twyman, Roy E.

PATENT ASSIGNEE(S): Ortho-McNeil Pharmaceutical, Inc., USA

SOURCE: PCT Int. Appl., 31 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002067927	A1	20020906	WO 2002-US6119	20020221
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
US 2002165272	A1	20021107	US 2002-81761	20020221
US 6541513	B2	20030401		

PRIORITY APPLN. INFO.: US 2001-271889P P 20010227
US 2002-81761 A 20020221

OTHER SOURCE(S): MARPAT 137:179915

REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

TI Phenyl carbamate compounds for use in preventing or treating **psychotic** disorders

AB This invention is directed to a method for preventing or treating **psychotic** disorders comprising administering to a subject in need thereof a therapeutically effective amt. of a compd. selected from the group consisting of formula I and formula II wherein X with one to five halogen atoms selected from the group consisting of fluorine, chlorine, bromine and iodine; and, R1-R6 are independently selected from the group

consisting of hydrogen and C1-C4 alkyl; wherein C1-C4 alkyl is optionally substituted with Ph (wherein Ph is optionally substituted with substituents independently selected from the group consisting of halogen, C1-C4 alkyl, C1-C4 alkoxy, amino, nitro and cyano). The **psychotic** disorders are selected from schizophrenia, schizophreniform disorder, schizo-affective disorder, delusional disorder, brief **psychotic** disorder, shared **psychotic** disorder, **psychotic** disorder due to a general medical condition, substance-induced **psychotic** disorder. The schizophrenia is selected from paranoid schizophrenia, hebephrenic schizophrenia, catatonic schizophrenia, undifferentiated schizophrenia, post-schizophrenic depression, residual schizophrenia, simple schizophrenia or unspecified schizophrenia. Thus, compds. I and II (x = ortho-C1, R1-R6 = H) were tested in rats in preventing or treating **psychotic** disorders. The therapeutically effective amt. is from about 0.01 mg/Kg/dose to about 100 mg/Kg/dose. phenyl carbamate treating **psychotic** disorder human

ST
IT

Human
Schizophrenia

(Ph carbamate compds. for use in preventing or treating
psychotic disorders)

IT

Schizophrenia

(catatonia; Ph carbamate compds. for use in preventing or treating
psychotic disorders)

IT

Mental disorder

(depression; Ph carbamate compds. for use in preventing or treating
psychotic disorders)

IT

Mental disorder

(psychosis; Ph carbamate compds. for use in preventing or treating
psychotic disorders)

IT

194085-58-0 194085-75-1

RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL
(Biological study); USES (Uses)

(Ph carbamate compds. for use in preventing or treating
psychotic disorders)

=> d 126 2-4 ibib, kwic

L26 ANSWER 2 OF 4 CAPLUS COPYRIGHT 2003 ACS on STN

ACCESSION NUMBER: 2002:675828 CAPLUS

DOCUMENT NUMBER: 137:179912

TITLE: Phenyl carbamate compounds for use in preventing or treating **bipolar** disorder

INVENTOR(S): Plata-Salaman, Carlos R.; Zhao, Boyu; Twyman, Roy E.; Choi, Yong Moon; Gordon, Robert

PATENT ASSIGNEE(S): Ortho-McNeil Pharmaceutical, Inc., USA

SOURCE: PCT Int. Appl., 24 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002067924	A1	20020906	WO 2002-US5425	20020221
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
US 2002193433	A1	20021219	US 2002-81606	20020221
PRIORITY APPLN. INFO.:			US 2001-271680P P	20010227
			US 2002-81606 A	20020221

OTHER SOURCE(S): MARPAT 137:179912

REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

TI Phenyl carbamate compounds for use in preventing or treating **bipolar** disorder

AB This invention is directed to a method for preventing or treating **bipolar** disorder comprising administering to a subject in need thereof a therapeutically effective amt. of a compd. of formula I; wherein Ph is substituted at X with one to five halogen atoms selected from the group consisting of fluorine, chlorine, bromine and iodine; and, R1-R4 are independently selected from the group consisting of hydrogen and C1-C4 alkyl; wherein C1-C4 alkyl is optionally substituted with Ph (wherein Ph is optionally substituted with substituents independently selected from the group consisting of halogen, C1-C4 alkyl, C1-C4 alkoxy, amino, nitro and cyano). **Bipolar** disorder is selected from the group consisting of **bipolar** disorder type I, **bipolar** disorder type II, cyclothymic disorder, rapid cycling, ultradian cycling, **bipolar** depression, acute mania, mania, mixed mania, hypomania and episodes assocd. with **bipolar** disorder. These compds., e.g. I (X = ortho-Cl, R1-R4 = H), were tested in rats for treatment against **bipolar** disorder and the therapeutically effective amt. is about 0.01 mg/Kg/dose to about 100 mg/Kg/dose.

ST human kindling muscle nervous system **bipolar** disorder phenyl carbamate; brain kindling muscle nervous system **bipolar** disorder phenyl carbamate

IT Human
Muscle
Muscle, disease
Nervous system
Nervous system, disease

(Ph carbamate compds. for use in preventing or treating **bipolar** disorder)

IT Mental disorder
(**bipolar** disorder; Ph carbamate compds. for use in preventing or treating **bipolar** disorder)

IT Brain, disease

(kindling; Ph carbamate compds. for use in preventing or treating
bipolar disorder)

IT Mental disorder

(mania; Ph carbamate compds. for use in preventing or treating
bipolar disorder)

IT 194085-58-0

RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL
(Biological study); USES (Uses)

(Ph carbamate compds. for use in preventing or treating **bipolar**
disorder)

L26 ANSWER 3 OF 4 USPATFULL on STN

ACCESSION NUMBER: 2002:338065 USPATFULL

TITLE: Carbamate compounds for use in preventing or treating
bipolar disorder

INVENTOR(S): Plata-Salaman, Carlos R., Ambler, PA, UNITED STATES
Zhao, Boyu, Lansdale, PA, UNITED STATES
Twyman, Roy E., Doylestown, PA, UNITED STATES
Choi, Yong Moon, Towaco, NJ, UNITED STATES
Gordon, Robert, Robbinsville, NJ, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2002193433	A1	20021219
APPLICATION INFO.:	US 2002-81606	A1	20020221 (10)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2001-271680P	20010227 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	AUDLEY A. CIAMPORCERO JR., JOHNSON & JOHNSON, ONE JOHNSON & JOHNSON PLAZA, NEW BRUNSWICK, NJ, 08933-7003	
NUMBER OF CLAIMS:	17	
EXEMPLARY CLAIM:	1	
LINE COUNT:	577	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

TI Carbamate compounds for use in preventing or treating **bipolar**
disorder

AB This invention is directed to a method for preventing or treating
bipolar disorder comprising administering to a subject in need
thereof a therapeutically effective amount of an enantiomer of Formula
(I) or.

SUMM [0002] This invention is directed to a method for use of a carbamate
compound in preventing or treating **bipolar** disorder. More
particularly, this invention is directed to a method for use of a
halogenated 2-phenyl-1,2-ethanediol dicarbamate enantiomer or
enantiomeric mixture wherein one enantiomer predominates for preventing
or treating **bipolar** disorder.

SUMM [0003] **Bipolar** disorder is a progressive psychiatric disorder
(F. Goodwin and K. R. Jamison, **Manic-Depressive**
Illness, Oxford University Press, New York, 1990). **Bipolar**
disorder is characterized by recurrent episodes of changes in mood. The
episodes may exhibit symptoms of mania, hypomania (less severe form of
mania), depression, or a combination of mania and depression (
Bipolar Disorder, Cognos Study #53, Decision Resources, March
2000). **Bipolar** disorder type I features more **manic**
or mixed mood symptoms, while **bipolar** disorder type II is
distinguished by primarily **depressive** episodes but also by
spontaneous hypomanic episodes (Diagnostic and Statistical Manual of
Mental Disorders, Edition 4, American Psychiatric Association,
Washington DC, 1994; **Bipolar** Disorder, Cognos Study #53,
Decision Resources, March 2000; Akiskal H. S., Bourgeois M. L., Angst
J., Post R., Moller H., Hirschfeld R., Re-evaluating the prevalence of
and diagnostic composition within the broad clinical spectrum of
bipolar disorders, J. Affect. Disord., 2000, 59 (Suppl 1),
S5-S30). Acute mania is associated with an elevated or irritable mood
and. . . J., Post R., Moller H., Hirschfeld R., Re-evaluating the
prevalence of and diagnostic composition within the broad clinical

spectrum of **bipolar** disorders, J. Affect. Disord., 2000, 59 (Suppl 1), S5-S30). Cyclothymic disorder is an attenuated **bipolar** disorder characterized by frequent short cycles of subsyndromal depression and hypomanic episodes (Diagnostic and Statistical Manual of Mental Disorders, Edition. . . .

SUMM [0004] Recurrences of **bipolar** disorder illness have been hypothesized to be caused by electrophysiologic/neurophysiologic kindling (F. Goodwin and K. R. Jamison, **Manic-Depressive** Illness, Oxford University Press, New York, pp 405-407, 1990; Ghaemi S. N., Boiman E. E., Goodwin F. K., Kindling and second messengers: an approach to the neurobiology of recurrence in **bipolar** disorder, Biol. Psychiatry, 1999, 45(2), 137-44; Stoll A. L., Severus W. E., Mood stabilizers: shared mechanisms of action at postsynaptic signal-transduction and kindling processes, Harv. Rev. Psychiatry, 1996, 4(2), 77-89; Goldberg J. F., Harrow M., Kindling in **bipolar** disorders: a longitudinal follow-up study, Biol. Psychiatry, 1994, 1; 35(1), 70-2).

SUMM [0005] Mood stabilizers are used to treat **bipolar** disorder (Sadock B. J., Sadock B. A., Post RM. Treatment of **bipolar** disorders, Comprehensive Textbook of Psychiatry, 2000, vol. 1, 1385-1430). Established mood stabilizers exhibit anti-kindling effects (Stoll A. L., Severus W. . . . Psychiatry, 1996, 4(2), 77-89). Anticonvulsants and anti-epileptics which show anti-kindling effects are important alternatives and adjuncts in the treatment of **bipolar** illness (Post R. M., Denicoff K. D., Frye M. A., Dunn R. T., Leverich G. S., Osuch E., Speer A., . . . stabilizers in the last two decades of the 20th century, Neuropsychobiology, 1998, 38(3), 152-66; Janowsky D. S., New Treatments of **Bipolar** Disorder, Curr. Psychiatry Rep., 1999, 1(2), 111-113) including in rapid cycling **bipolar** disorder (Shelton M. D., Calabrese J. R., Current Concepts in Rapid Cycling **Bipolar** Disorder, Curr. Psychiatry Rep., 2000, 2(4), 310-315) and in the treatment and prevention of acute mania (Lennkh C., Simhandl C., Current aspects of valproate in **bipolar** disorder, Int. Clin. Psychopharmacol, 2000, 15(1), 1-11; Tohen M., Grundy S., Management of acute mania, J. Clin. Psychiatry, 1999, 60. . . . S., Printz D. J., Kahn D. A., Carpenter D., Docherty J. P., The Expert Consensus Guideline Series: Medication Treatment of **Bipolar** Disorder 2000. Postgrad. Med., 2000, Spec No:1-104).

SUMM . . . enantiomeric mixture wherein one enantiomer of Formula (I) predominates has not been previously described as useful for preventing or treating **bipolar** disorder. Recent preclinical studies have revealed previously unrecognized pharmacological properties which suggest that an enantiomer of Formula (I) or enantiomeric mixture wherein one enantiomer of Formula (I) predominates is useful in preventing or treating **bipolar** disorder. Therefore, it is an object of the present invention to teach a method for use of an enantiomer of Formula (I) or enantiomeric mixture wherein one enantiomer of Formula (I) predominates in preventing or treating **bipolar** disorder.

SUMM [0014] The present invention is directed to a method for preventing or treating **bipolar** disorder comprising administering to a subject in need thereof a therapeutically effective amount of an enantiomer of Formula (I) or. . . .

SUMM [0018] Embodiments of the invention include a method for preventing or treating **bipolar** disorder comprising administering to a subject in need thereof a therapeutically effective amount of a pharmaceutical composition comprising a pharmaceutically. . . .

SUMM . . . or enantiomeric mixture wherein one enantiomer of Formula (I) predominates for the preparation of a medicament for preventing or treating **bipolar** disorder in a subject in need thereof.

SUMM [0021] The present invention is directed to a method for preventing or treating **bipolar** disorder comprising administering to a subject in need thereof a therapeutically effective amount of an enantiomer of Formula (I) or. . . .

SUMM [0025] An embodiment of the invention includes a method for slowing or delaying the progression of **bipolar** disorder comprising administering to a subject in need thereof a therapeutically effective amount of an enantiomer of Formula (I) or. . . .

SUMM [0036] An embodiment of the present method includes a method for

preventing or treating **bipolar** disorder comprising administering to a subject in need thereof a therapeutically effective amount of an enantiomer of Formula (Ib) or. . .

SUMM [0038] An embodiment of the invention includes a method for slowing or delaying the progression of **bipolar** disorder comprising administering to a subject in need thereof a therapeutically effective amount of an enantiomer of Formula (Ib).

SUMM [0043] The present invention contemplates a method for preventing or treating **bipolar** disorder in a subject in need thereof. **Bipolar** disorder includes, and is not limited to, **bipolar** disorder type I, **bipolar** disorder type II, cyclothymic disorder, rapid cycling, ultradian cycling, **bipolar** depression, acute mania, mania, mixed mania, hypomania or episodes associated with **bipolar** disorder.

SUMM . . . or enantiomeric mixture wherein one enantiomer of Formula (I) predominates for the preparation of a medicament for preventing or treating **bipolar** disorder.

SUMM . . . Formula (I) predominates or a pharmaceutical composition thereof in combination with one or more agents useful in preventing or treating **bipolar** disorder.

SUMM . . . Formula (I) or enantiomeric mixture wherein one enantiomer of Formula (I) predominates or pharmaceutical composition thereof for preventing or treating **bipolar** disorder is administered orally or parenterally.

DETD . . . of Formula (I) (or an enantiomeric mixture wherein one enantiomer of Formula (I) predominates) for use in preventing or treating **bipolar** disorder was evaluated in the following experimental examples which are intended to be a way of illustrating but not limiting. . .

DETD . . . kindling model (Lothman E W, et al., Epilepsy Res., 1988, 2(6) 367-79), adult male Sprague-Dawley rats are surgically implanted with **bipolar** electrodes. Seizure score is assessed as follows: (1) mouth and facial movements; (2) above symptoms plus head nodding; (3) above. . .

CLM What is claimed is:
 1. A method for preventing or treating **bipolar** disorder comprising administering to a subject in need thereof a therapeutically effective amount of an enantiomer of Formula (I) or. . .
 14. The method of claim 1 wherein **bipolar** disorder is selected from the group consisting of **bipolar** disorder type I, **bipolar** disorder type II cyclothymic disorder, rapid cycling, ultradian cycling, **bipolar** depression, acute mania, mania, mixed mania, hypomania and episodes associated with **bipolar** disorder.
 16. The method of claim 1 wherein the method is a method for slowing or delaying the progression of **bipolar** disorder comprising administering to a subject in need thereof a therapeutically effective amount of an enantiomer of Formula (I) or. . .

IT 194085-58-0
 (Ph carbamate compds. for use in preventing or treating bipolar disorder)

L26 ANSWER 4 OF 4 USPATFULL on STN
 ACCESSION NUMBER: 2002:295223 USPATFULL
 TITLE: CARBAMATE COMPOUNDS FOR USE IN PREVENTING OR TREATING PSYCHOTIC DISORDERS
 INVENTOR(S): Plata-Salaman, Carlos R., Ambler, PA, UNITED STATES
 Zhao, Boyu, Lansdale, PA, UNITED STATES
 Twyman, Roy E., Doylestown, PA, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2002165272	A1	20021107
	US 6541513	B2	20030401
APPLICATION INFO.:	US 2002-81761	A1	20020221 (10)

NUMBER	DATE
-----	-----

PRIORITY INFORMATION: US 2001-271889P 20010227 (60)
DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: AUDLEY A. CIAMPORCERO JR., JOHNSON & JOHNSON, ONE
JOHNSON & JOHNSON PLAZA, NEW BRUNSWICK, NJ, 08933-7003
NUMBER OF CLAIMS: 22
EXEMPLARY CLAIM: 1
LINE COUNT: 733

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

TI CARBAMATE COMPOUNDS FOR USE IN PREVENTING OR TREATING **PSYCHOTIC**
DISORDERS

AB This invention is directed to a method for preventing or treating
psychotic disorders comprising administering to a subject in
need thereof a therapeutically effective amount of a compound selected
from the group.

SUMM [0002] This invention is directed to a method for use of a carbamate
compound in preventing or treating **psychotic** disorders. More
particularly, this invention is directed to a method for use of
halogenated 2-phenyl-1,2-ethanediol monocarbamate or dicarbamate
compounds for preventing or treating **psychotic** disorders.

SUMM [0003] **Psychotic** disorders are those that are predominantly
characterized by psychosis. Psychosis is an impairment of mental
functioning to the extent that. . . it interferes grossly with an
individual's ability to meet the ordinary demands of life. According to
the American Psychiatric Association, **psychotic** means grossly
impaired, in terms of reality testing. Such testing would define gross
impairment as existing when individuals incorrectly evaluate. . .
their perceptions and thoughts and make incorrect inferences about
external reality, even in the face of contrary evidence. The term
psychotic is also appropriate when behavior is so disorganized
that it is reasonable to infer that results of reality testing would.
. . . the person that the speech is not understandable or by the agitated,
inattentive and disoriented behavior observed in the phencyclidine
psychotic disorder (Diagnostic and Statistical Manual of Mental
Disorders, Ed. 4.sup.th, American Psychiatric Association, Washington,
D.C. 1994; Kaplan & Sadock's Comprehensive.

SUMM [0004] **Psychotic** disorders include, and are not limited to,
schizophrenia, schizophreniform disorder, schizoaffective disorder,
delusional disorder, brief **psychotic** disorder, shared
psychotic disorder, **psychotic** disorder due to a
general medical condition, substance-induced **psychotic**
disorder or **psychotic** disorder not otherwise specified
(Diagnostic and Statistical Manual of Mental Disorders, Ed. 4.sup.th,
American Psychiatric Association, Washington, D.C. 1994).

SUMM [0005] Schizophrenia is any of a group of **psychotic** disorders
usually characterized by withdrawal from reality, illogical patterns of
thinking, delusions and hallucinations and accompanied in varying
degrees by.

SUMM . . . Bull., 2000, 51 (1), 75-81; Wettstein J G, Host M, Hitchcock J
M, Selectivity of action of typical and atypical anti-**psychotic**
drugs as antagonists of the behavioral effects of 1-[2,5-dimethoxy-4-
iodophenyl]-2-aminopropane (DOI), Prog. Neuropsychopharmacol. Biol.
Psychiatry, 1999, 23 (3), 533-44). In the. . . non-antipsychotic
drugs were generally inactive (Wettstein J G, Host M, Hitchcock J M,
Selectivity of action of typical and atypical anti-**psychotic**
drugs as antagonists of the behavioral effects of 1-[2,5-dimethoxy-4-
iodophenyl]-2-aminopropane (DOI), Prog. Neuropsychopharmacol. Biol.
Psychiatry, 1999 April 23 (3), 533-44).

SUMM . . . 2-phenyl-1,2-ethanediol carbamate compounds of Formula (I) or
Formula (II) have not been previously described as useful for preventing
or treating **psychotic** disorders. Recent preclinical studies
have revealed previously unrecognized pharmacological properties which
suggest that a compound of Formula (I) or Formula (II) is useful in
preventing or treating **psychotic** disorders. Therefore, it is
an object of the present invention to teach a method for use of a
compound of Formula (I) or Formula (II) in preventing or treating
psychotic disorders.

SUMM [0019] The present invention is directed to a method for preventing or
treating **psychotic** disorders comprising administering to a

subject in need thereof a therapeutically effective amount of a compound selected from the group. . . .

SUMM [0023] Embodiments of the invention include a method for preventing or treating **psychotic** disorders comprising administering to a subject in need thereof a therapeutically effective amount of a pharmaceutical composition comprising a pharmaceutically. . . .

SUMM from the group consisting of Formula (I) and Formula (II) for the preparation of a medicament for preventing or treating **psychotic** disorders in a subject in need thereof.

SUMM [0026] The present invention is directed to a method for preventing or treating **psychotic** disorders comprising administering to a subject in need thereof a therapeutically effective amount of a compound selected from the group. . . .

SUMM [0042] An embodiment of the present method includes a method for preventing or treating **psychotic** disorders comprising administering to a subject in need thereof a therapeutically effective amount of an enantiomer selected from the group. . . .

SUMM [0048] The present invention contemplates a method for preventing or treating **psychotic** disorders in a subject in need thereof.

Psychotic disorders include, and are not limited to, schizophrenia, schizophreniform disorder, schizoaffective disorder, delusional disorder, brief **psychotic** disorder, shared **psychotic** disorder, **psychotic** disorder due to a general medical condition, substance-induced **psychotic** disorder or **psychotic** disorder not otherwise specified. More particularly, schizophrenia includes, and is not limited to, paranoid schizophrenia, hebephrenic schizophrenia, catatonic schizophrenia, undifferentiated. . . .

SUMM from the group consisting of Formula (I) and Formula (II) for the preparation of a medicament for preventing or treating **psychotic** disorders.

SUMM and Formula (II) or a pharmaceutical composition thereof in combination with one or more agents useful in preventing or treating **psychotic** disorders.

SUMM post-periodic dosing may be employed. Preferably, a compound of Formula (I) or Formula (II) or pharmaceutical composition thereof for treating **psychotic** disorders is administered orally or parenterally.

DETD [0065] The activities of a compound of Formula (I) and Formula (II) for use in preventing or treating **psychotic** disorders were evaluated in the following experimental example which is intended to be a way of illustrating but not limiting. . . .

CLM What is claimed is:

1. A method for preventing or treating **psychotic** disorders comprising administering to a subject in need thereof a therapeutically effective amount of a compound selected from the group. . . .
5. A method for preventing or treating **psychotic** disorders comprising administering to a subject in need thereof a therapeutically effective amount of an enantiomer selected from the group. . . .
20. The method as in claims 1 or 5 wherein **psychotic** disorders are selected from schizophrenia, schizophreniform disorder, schizoaffective disorder, delusional disorder, brief **psychotic** disorder, shared **psychotic** disorder, **psychotic** disorder due to a general medical condition, substance-induced **psychotic** disorder or **psychotic** disorder not otherwise specified.

IT 194085-58-0 194085-75-1

(Ph carbamate compds. for use in preventing or treating psychotic disorders)

=> file reg

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

0.21

0.21

FILE 'REGISTRY' ENTERED AT 15:14:09 ON 02 SEP 2003

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2003 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 1 SEP 2003 HIGHEST RN 577691-42-0

DICTIONARY FILE UPDATES: 1 SEP 2003 HIGHEST RN 577691-42-0

TSCA INFORMATION NOW CURRENT THROUGH JANUARY 6, 2003

Please note that search-term pricing does apply when conducting SmartSELECT searches.

Crossover limits have been increased. See HELP CROSSOVER for details.

Experimental and calculated property data are now available. See HELP PROPERTIES for more information. See STNote 27, Searching Properties in the CAS Registry File, for complete details:

<http://www.cas.org/ONLINE/STN/STNOTES/stnotes27.pdf>

=> s 194085580p/rn

L1 0 194085580P/RN

=> s 194085-67-1p/rn

L2 0 194085-67-1P/RN

=> s 19408558-0/rn

INCONSISTENT NUMERIC RANGE EXPRESSION '19408558-0'

The lower limit in a numeric range must be given before the upper limit. For example, '5-1/C' is not valid. The correct form is '1-5/C'.

=> s 194085-58-0/rn

L3 1 194085-58-0/RN

=> d l3

L3 ANSWER 1 OF 1 REGISTRY COPYRIGHT 2003 ACS on STN

RN 194085-58-0 REGISTRY

CN 1,2-Ethanediol, 1-(2-chlorophenyl)-, dicarbamate, (1R)- (9CI) (CA INDEX NAME)

OTHER CA INDEX NAMES:

CN 1,2-Ethanediol, 1-(2-chlorophenyl)-, dicarbamate, (R)-


FS STEREOSEARCH

MF C10 H11 Cl N2 O4

SR CA

LC STN Files: CA, CAPLUS, CASREACT, USPAT2, USPATFULL

Absolute stereochemistry. Rotation (+).



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

10 REFERENCES IN FILE CA (1937 TO DATE)
10 REFERENCES IN FILE CAPLUS (1937 TO DATE)

=> s 194085-67-1/rn

L4 1 194085-67-1/RN

=> d 14

L4 ANSWER 1 OF 1 REGISTRY COPYRIGHT 2003 ACS on STN

RN 194085-67-1 REGISTRY

CN Carbamic acid, (1-methylethyl)-, (1R)-2-[(aminocarbonyl)oxy]-1-(2-chlorophenyl)ethyl ester (9CI) (CA INDEX NAME)

OTHER CA INDEX NAMES:

CN Carbamic acid, (1-methylethyl)-, 2-[(aminocarbonyl)oxy]-1-(2-chlorophenyl)ethyl ester, (R)-


FS STEREOSEARCH

MF C13 H17 Cl N2 O4

SR CA

LC STN Files: CA, CAPLUS, USPATFULL

Absolute stereochemistry. Rotation (+).



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

3 REFERENCES IN FILE CA (1937 TO DATE)
3 REFERENCES IN FILE CAPLUS (1937 TO DATE)

=> s 194085-57-9/rn

L5 1 194085-57-9/RN

=> d 15

L5 ANSWER 1 OF 1 REGISTRY COPYRIGHT 2003 ACS on STN

RN 194085-57-9 REGISTRY


CN 1,2-Ethanediol, 1-(2-chlorophenyl)-, dicarbamate (9CI) (CA INDEX NAME)

FS 3D CONCORD

MF C10 H11 Cl N2 O4

SR CA

LC STN Files: CA, CAPLUS, CASREACT, USPATFULL




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

4 REFERENCES IN FILE CA (1937 TO DATE)
1 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
4 REFERENCES IN FILE CAPLUS (1937 TO DATE)

=> s 194085-61-5/rn
L6 1 194085-61-5/RN

=> d 16

L6 ANSWER 1 OF 1 REGISTRY COPYRIGHT 2003 ACS on STN
RN 194085-61-5 REGISTRY
CN 1,2-Ethanediol, 1-(4-chlorophenyl)-, dicarbamate (9CI) (CA INDEX NAME)
FS 3D CONCORD
MF C10 H11 Cl N2 O4
SR CA
LC STN Files: CA, CAPLUS, USPATFULL




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

3 REFERENCES IN FILE CA (1937 TO DATE)
3 REFERENCES IN FILE CAPLUS (1937 TO DATE)

=> s 194085-64-8/rn
L7 1 194085-64-8/RN

=> d 17

L7 ANSWER 1 OF 1 REGISTRY COPYRIGHT 2003 ACS on STN
RN 194085-64-8 REGISTRY
CN 1,2-Ethanediol, 1-(2,6-dichlorophenyl)-, dicarbamate (9CI) (CA INDEX NAME)
FS 3D CONCORD
MF C10 H10 Cl2 N2 O4
SR CA
LC STN Files: CA, CAPLUS, USPATFULL



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT


3 REFERENCES IN FILE CA (1937 TO DATE)
3 REFERENCES IN FILE CAPLUS (1937 TO DATE)

=> s 194085-68-2/rn
L8 1 194085-68-2/RN

=> d 18

L8 ANSWER 1 OF 1 REGISTRY COPYRIGHT 2003 ACS on STN
RN 194085-68-2 REGISTRY
CN Carbamic acid, cyclopropyl-, (1R)-2-[(aminocarbonyl)oxy]-1-(2-chlorophenyl)ethyl ester (9CI) (CA INDEX NAME)
OTHER CA INDEX NAMES:
CN Carbamic acid, cyclopropyl-, 2-[(aminocarbonyl)oxy]-1-(2-chlorophenyl)ethyl ester, (R)-
FS STEREOSEARCH
MF C13 H15 Cl N2 O4
SR CA
LC STN Files: CA, CAPLUS, USPATFULL

Absolute stereochemistry. Rotation (+).



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT


3 REFERENCES IN FILE CA (1937 TO DATE)
3 REFERENCES IN FILE CAPLUS (1937 TO DATE)

=> s 194085-71-7/rn
L9 1 194085-71-7/RN

=> d 19

L9 ANSWER 1 OF 1 REGISTRY COPYRIGHT 2003 ACS on STN
RN 194085-71-7 REGISTRY
CN 1,2-Ethanediol, 1-(2-chlorophenyl)-, bis(phenylcarbamate), (1R)- (9CI)
(CA INDEX NAME)
OTHER CA INDEX NAMES:
CN 1,2-Ethanediol, 1-(2-chlorophenyl)-, bis(phenylcarbamate), (R)-
FS STEREOSEARCH
MF C22 H19 Cl N2 O4
SR CA
LC STN Files: CA, CAPLUS, USPATFULL

Absolute stereochemistry.




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

3 REFERENCES IN FILE CA (1937 TO DATE)
3 REFERENCES IN FILE CAPLUS (1937 TO DATE)

=> s 194085-60-4/rn
L10 1 194085-60-4/RN

=> d l10

L10 ANSWER 1 OF 1 REGISTRY COPYRIGHT 2003 ACS on STN
RN 194085-60-4 REGISTRY
CN 1,2-Ethanediol, 1-(3-chlorophenyl)-, dicarbamate (9CI) (CA INDEX NAME)
FS 3D CONCORD
MF C10 H11 Cl N2 O4
SR CA
LC STN Files: CA, CAPLUS, USPATFULL




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

3 REFERENCES IN FILE CA (1937 TO DATE)
3 REFERENCES IN FILE CAPLUS (1937 TO DATE)

=> s 194085-60-4/rn
L11 1 194085-60-4/RN

=> d l11

L11 ANSWER 1 OF 1 REGISTRY COPYRIGHT 2003 ACS on STN
RN 194085-60-4 REGISTRY
CN 1,2-Ethanediol, 1-(3-chlorophenyl)-, dicarbamate (9CI) (CA INDEX NAME)
FS 3D CONCORD
MF C10 H11 Cl N2 O4
SR CA
LC STN Files: CA, CAPLUS, USPATFULL




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

3 REFERENCES IN FILE CA (1937 TO DATE)
3 REFERENCES IN FILE CAPLUS (1937 TO DATE)

=> s 194085-61-5/rn
L12 1 194085-61-5/RN

=> d l12

L12 ANSWER 1 OF 1 REGISTRY COPYRIGHT 2003 ACS on STN
RN 194085-61-5 REGISTRY
CN 1,2-Ethanedithiol, 1-(4-chlorophenyl)-, dicarbamate (9CI) (CA INDEX NAME)
FS 3D CONCORD
MF C10 H11 Cl N2 O4
SR CA
LC STN Files: CA, CAPLUS, USPATFULL



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT


3 REFERENCES IN FILE CA (1937 TO DATE)
3 REFERENCES IN FILE CAPLUS (1937 TO DATE)

=> s 194085-62-6/rn
L13 1 194085-62-6/RN

=> d l13

L13 ANSWER 1 OF 1 REGISTRY COPYRIGHT 2003 ACS on STN
RN 194085-62-6 REGISTRY
CN 1,2-Ethanedithiol, 1-(4-chlorophenyl)-, dicarbamate, (1R)- (9CI) (CA INDEX NAME)
OTHER CA INDEX NAMES:
CN 1,2-Ethanedithiol, 1-(4-chlorophenyl)-, dicarbamate, (R)-
FS STEREOSEARCH
MF C10 H11 Cl N2 O4
SR CA
LC STN Files: CA, CAPLUS, USPATFULL

Absolute stereochemistry. Rotation (-).



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT


3 REFERENCES IN FILE CA (1937 TO DATE)
3 REFERENCES IN FILE CAPLUS (1937 TO DATE)

=> s 194085-63-7/rn
L14 1 194085-63-7/RN

=> d 114

L14 ANSWER 1 OF 1 REGISTRY COPYRIGHT 2003 ACS on STN
RN 194085-63-7 REGISTRY
CN 1,2-Ethanediol, 1-(4-chlorophenyl)-, dicarbamate, (1S)- (9CI) (CA INDEX NAME)
OTHER CA INDEX NAMES:
CN 1,2-Ethanediol, 1-(4-chlorophenyl)-, dicarbamate, (S)-
FS STEREOSEARCH
MF C10 H11 Cl N2 O4
SR CA
LC STN Files: CA, CAPLUS, USPATFULL

Absolute stereochemistry. Rotation (+).




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

3 REFERENCES IN FILE CA (1937 TO DATE)
3 REFERENCES IN FILE CAPLUS (1937 TO DATE)

=> s 194085-64-8/rn
L15 1 194085-64-8/RN

=> d 115

L15 ANSWER 1 OF 1 REGISTRY COPYRIGHT 2003 ACS on STN
RN 194085-64-8 REGISTRY
CN 1,2-Ethanediol, 1-(2,6-dichlorophenyl)-, dicarbamate (9CI) (CA INDEX NAME)
FS 3D CONCORD
MF C10 H10 Cl2 N2 O4
SR CA
LC STN Files: CA, CAPLUS, USPATFULL



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT


3 REFERENCES IN FILE CA (1937 TO DATE)
3 REFERENCES IN FILE CAPLUS (1937 TO DATE)

=> s 194085-65-9/rn
L16 1 194085-65-9/RN

=> d 116

L16 ANSWER 1 OF 1 REGISTRY COPYRIGHT 2003 ACS on STN
RN 194085-65-9 REGISTRY
CN 1,2-Ethanediol, 1-(2,6-dichlorophenyl)-, dicarbamate, (1R)- (9CI) (CA INDEX NAME)
OTHER CA INDEX NAMES:
CN 1,2-Ethanediol, 1-(2,6-dichlorophenyl)-, dicarbamate, (R)-
FS STEREOSEARCH
MF C10 H10 Cl2 N2 O4
SR CA
LC STN Files: CA, CAPLUS, USPATFULL

Absolute stereochemistry. Rotation (+).



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

3 REFERENCES IN FILE CA (1937 TO DATE)
3 REFERENCES IN FILE CAPLUS (1937 TO DATE)


=> s 194085-66-0/rn
L17 1 194085-66-0/RN

=> d 117

L17 ANSWER 1 OF 1 REGISTRY COPYRIGHT 2003 ACS on STN
RN 194085-66-0 REGISTRY
CN 1,2-Ethanediol, 1-(2-chlorophenyl)-, 2-carbamate 1-(methylcarbamate), (1R)- (9CI) (CA INDEX NAME)
OTHER CA INDEX NAMES:
CN 1,2-Ethanediol, 1-(2-chlorophenyl)-, 2-carbamate 1-(methylcarbamate), (R)-
FS STEREOSEARCH

MF C11 H13 Cl N2 O4
SR CA
LC STN Files: CA, CAPLUS, USPATFULL

Absolute stereochemistry. Rotation (+).



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT


3 REFERENCES IN FILE CA (1937 TO DATE)
3 REFERENCES IN FILE CAPLUS (1937 TO DATE)

=> s 194085-68-2/rn
L18 1 194085-68-2/RN

=> d 118

L18 ANSWER 1 OF 1 REGISTRY COPYRIGHT 2003 ACS on STN
RN 194085-68-2 REGISTRY
CN Carbamic acid, cyclopropyl-, (1R)-2-[(aminocarbonyl)oxy]-1-(2-chlorophenyl)ethyl ester (9CI) (CA INDEX NAME)
OTHER CA INDEX NAMES:
CN Carbamic acid, cyclopropyl-, 2-[(aminocarbonyl)oxy]-1-(2-chlorophenyl)ethyl ester, (R)-
FS STEREOSEARCH
MF C13 H15 Cl N2 O4
SR CA
LC STN Files: CA, CAPLUS, USPATFULL

Absolute stereochemistry. Rotation (+).



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT


3 REFERENCES IN FILE CA (1937 TO DATE)
3 REFERENCES IN FILE CAPLUS (1937 TO DATE)

=> s 194085-69-3/rn
L19 1 194085-69-3/RN

=> d 119

L19 ANSWER 1 OF 1 REGISTRY COPYRIGHT 2003 ACS on STN
 RN 194085-69-3 REGISTRY
 CN 1,2-Ethanediol, 1-(2-chlorophenyl)-, bis(methylcarbamate), (1R)- (9CI)
 (CA INDEX NAME)
 OTHER CA INDEX NAMES:
 CN 1,2-Ethanediol, 1-(2-chlorophenyl)-, bis(methylcarbamate), (R)-
 FS STEREOSEARCH
 MF C12 H15 Cl N2 O4
 SR CA
 LC STN Files: CA, CAPLUS, USPATFULL

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT


3 REFERENCES IN FILE CA (1937 TO DATE)
 3 REFERENCES IN FILE CAPLUS (1937 TO DATE)

=> s 194085-70-6/rn
 L20 1 194085-70-6/RN

=> d l20

L20 ANSWER 1 OF 1 REGISTRY COPYRIGHT 2003 ACS on STN
 RN 194085-70-6 REGISTRY
 CN Carbamic acid, (1-methylethyl)-, (1R)-1-(2-chlorophenyl)-1,2-ethanediyl
 ester (9CI) (CA INDEX NAME)
 FS STEREOSEARCH
 MF C16 H23 Cl N2 O4
 SR CA
 LC STN Files: CA, CAPLUS, USPATFULL

Absolute stereochemistry. Rotation (+).



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT


3 REFERENCES IN FILE CA (1937 TO DATE)
 3 REFERENCES IN FILE CAPLUS (1937 TO DATE)

=> s 194085-71-7/rn
 L21 1 194085-71-7/RN

=> d 121

L21 ANSWER 1 OF 1 REGISTRY COPYRIGHT 2003 ACS on STN
RN 194085-71-7 REGISTRY
CN 1,2-Ethanediol, 1-(2-chlorophenyl)-, bis(phenylcarbamate), (1R)- (9CI)
(CA INDEX NAME)
OTHER CA INDEX NAMES:
CN 1,2-Ethanediol, 1-(2-chlorophenyl)-, bis(phenylcarbamate), (R)-
FS STEREOSEARCH
MF C22 H19 Cl N2 O4
SR CA
LC STN Files: CA, CAPLUS, USPATFULL

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT


3 REFERENCES IN FILE CA (1937 TO DATE)
3 REFERENCES IN FILE CAPLUS (1937 TO DATE)

=> s 194085-72-8/rn
L22 1 194085-72-8/RN

=> d 122

L22 ANSWER 1 OF 1 REGISTRY COPYRIGHT 2003 ACS on STN
RN 194085-72-8 REGISTRY
CN Carbamic acid, (phenylmethyl)-, (1R)-1-(2-chlorophenyl)-1,2-ethanediyl
ester (9CI) (CA INDEX NAME)
FS STEREOSEARCH
MF C24 H23 Cl N2 O4
SR CA
LC STN Files: CA, CAPLUS, USPATFULL

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

3 REFERENCES IN FILE CA (1937 TO DATE)
3 REFERENCES IN FILE CAPLUS (1937 TO DATE)